Loading
Sygnis S.A. is a listed company. Filings by its managers are published through KNF. In the past year (24 October 2025 to 24 October 2026), 2 filings came from 2 insiders.
All open-market trades in the period are sales: 1 sale worth €1.9M, by 1 insider, with no purchase on record. Biggest ticket of the year: €1.9M, sold by Andrzej Burgs and made public on 2 March 2026.
For context, the typical company on the same exchange (median of 554 companies) published 3 filings over the same period, against 2 filings here. The full history, which starts in 2026, counts no purchases against 1 sale.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Every figure here comes from the filings published by KNF and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
2 of 2 declarations
Sygnis S.A. is a company listed on the XWAR market, specializing in the development of technological solutions for the biotechnology sector. It focuses on innovation in the fields of research and diagnostics.